Victor J. Aresty Professor of Medicine, Beth Israel Deaconess Medical Center
Nephrology
Dr. Vikas P. Sukhatme, MD
|
|
Give Review
Vikas P. Sukhatme practices Nephrology. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 2 awards "Elected Member" and "Investigator Alumnus". Vikas Sukhatme is a published doctor and has 65 publications published. The lastest was: 'Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP.'
Publications
- Drug repurposing in oncology-patient and health systems opportunities.
- Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP.
- Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells.
- Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.
- Modeling precision treatment of breast cancer.
- One-step purification of soluble recombinant human 6-phosphogluconate dehydrogenase from Escherichia coli.
- 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.
- Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.
- Conversion of Peripheral Blood NK Cells to a Decidual NK-like Phenotype by a Cocktail of Defined Factors.
- Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.
- Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence.
- A small-molecule screening strategy to identify suppressors of statin myopathy.
- Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylino...
- A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
- Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.
- Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect.
- Drug discovery. Repurposing with a difference.
- LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
- Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro.
- Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo.
- Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules.
- Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome.
- The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.
- Admission angiopoietin levels in children with septic shock.
- Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival.
- Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo.
- Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
- Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
- Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
- Biomarkers for monitoring antiangiogenic therapy.
- Nephrocan, a novel member of the small leucine-rich repeat protein family, is an inhibitor of transforming growth factor-beta signaling.
- Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells.
- Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
- Soluble endoglin contributes to the pathogenesis of preeclampsia.
- Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint.
- A critical role for calponin 2 in vascular development.
- Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans.
- Magic roundabout, a tumor endothelial marker: expression and signaling.
- Preeclampsia: a renal perspective.
- roundabout4 is essential for angiogenesis in vivo.
- Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells.
- Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression.
- Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
- Urinary placental growth factor and risk of preeclampsia.
- Critical roles of CD146 in zebrafish vascular development.
- Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance.
- Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights.
- Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia.
- Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3.
- Circulating angiogenic factors and the risk of preeclampsia.
- First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.
- Antiangiogenic property of human thrombin.
- Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo.
- In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.
- A refined understanding of immunosuppressives and cancer risk.
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
- Endostatin is a potential inhibitor of Wnt signaling.
- A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium.
- Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.
- Cellular actions and signaling by endostatin.
- Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.
- ATP citrate lyase knockdown impacts cancer stem cells in vitro.
- Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.
- Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling.
Schools
Harvard Medical School
Massachusetts General Hospital
Doctors Specialties
- Internal Medicine
- Nephrology
Accepted Insurances
- Great West Healthcare-Cigna PPO
Awards
- Elected Member
- Investigator Alumnus
Education
-
Stanford University -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Beth Israel Deaconess Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. James S. Kaufman, MD |
|
|
Dr. John K. Tucker, MD |
|
|
Dr. Stewart H. Lecker, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lipi Roy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jordan S. Leyton-Mange, MD |
|
|
Dr. Bruce J. Biller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leyda D. Delgado, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Castaldi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivian E. Abernethy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eva B. Long, MD |